Background: Acute exacerbation of chronic fibrosing interstitial pneumonia (AE-CFIP) is an often fatal condition with no established treatment. Recently, macrolides were found to be beneficial in cases of acute lung injury. Objectives: To examine the clinical effectiveness and safety of intravenous azithromycin in patients hospitalized for AE-CFIP. Methods: A prospective, open-label study with historical controls was conducted. Twenty consecutive patients with AE-CFIP received azithromycin. They were compared with a historical cohort treated with fluoroquinolone (n = 56). All patients received high-dose steroid pulse therapy. The primary end point was mortality at 60 days. The secondary end point was safety of intravenous azithromycin in patients with AE-CFIP. Inverse probability of treatment weighting (IPTW) using the propensity score was performed to investigate the relationship between azithromycin use and survival time. Results: Mortality was significantly lower in the patients treated with azithromycin than in those treated with fluoroquinolone (mortality rate at 60 days: 20 vs. 69.6%, p < 0.001; median survival time: not reached vs. 29.5 days, p < 0.001). The IPTW adjusted hazard of mortality at 60 days in patients receiving azithromycin was 0.17 (95% CI 0.05-0.61). No serious adverse events were observed. Conclusions: Azithromycin was associated with improved outcomes in patients with AE-CFIP. Further studies are needed to verify this finding (Clinical trial JMA-IIA00095).

Keywords:
Acute exacerbation, Azithromycin, Chronic fibrosing interstitial pneumonia, Idiopathic pulmonary fibrosis
1.
Raghu G, Collard HR, Egan JJ, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2.
Collard HR, Moore BB, Flaherty KR, et al: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-643.
3.
Park IN, Kim DS, Shim TS, et al: Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007;132:214-220.
4.
Miyazaki Y, Tateishi T, Akashi T, et al: Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 2008;134:1265-1270.
5.
Walkey AJ, Wiener RS: Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012;141:1153-1159.
6.
ATS, ERS: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
7.
Ohtani Y, Saiki S, Kitaichi M, et al: Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 2005;60:665-671.
8.
Azuma A, Nukiwa T, Tsuboi E, et al: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-1047.
9.
Ichikado K, Suga M, Müller NL, et al: Acute interstitial pneumonia. Am J Respir Crit Care Med 2002;165:1551-1556.
10.
Fernandez-Perez ER, Yilmaz M, Jenad H, et al: Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease. Chest 2008;133:1113-1119.
11.
Akira M, Kozuka T, Yamamoto S, et al: Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:372-378.
12.
Song JW, Hong S-B, Lim C-M, et al: Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356-363.
13.
Simon-Blancal V, Freynet O, Nunes H, et al: Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration 2012;83:28-35.
14.
Kondoh Y, Taniguchi H, Kimura T, Kataoka K: Recombinant thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. B102. Interstitial lung disease: novel management and outcome strategies. American Thoracic Society International Conference Abstracts, A3811.
15.
Austin PC: The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 2013;32:2837-2849.
16.
Al-hameed F, Sharma S, Sciberras D, et al: Outcome of patients admitted to intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Canad Respir J 2004;11:117-122.
17.
Kim DS, Park JH, Park BK, et al: Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27:143-150.
18.
Okamoto T, Ichiyasu H, Ichikado K, et al: Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi 2006;44:359-367.
19.
Kanoh S, Rubin BK: Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615.
20.
Zarogoulidis P, Papanas N, Kioumis I, et al: Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68:479-503.
21.
Damjanovic D, Lai R, Jeyanathan M, et al: Marked improvement of severe lung immunopathology by influenza-associated pneumococcal superinfection requires the control of both bacterial replication and host immune responses. Am J Pathol 2013, DOI: 10.1016/j.ajpath.2013.05.016.
22.
Ray WA, Murray KT, Hall K, et al: Azithromycin and the risk of cardiovascular death. New Engl J Med 2012;366:1881-1890.
23.
Svanström H, Pasternak B, Hviid A: Use of azithromycin and death from cardiovascular causes. New Engl J Med 2013;368:1704-1712.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.